Pharmaceuticals

May 30, 2019

Pharmaceuticals is a peer-reviewed open access journal of medicinal chemistry and related drug sciences.

Spotlight

Rational Vaccines

Rational Vaccines (RVx) was formed in 2015 for the purpose of offering better solutions to stop the spread of herpes and alleviate the problems faced by people suffering with unrelenting, chronic disease. Based on the life work of Dr. Bill Halford, Associate Professor, Southern Illinois University Medical School, who studied herpes simplex virus 1 and 2 (HSV-1 and HSV-2) in a laboratory setting for 25 years, RVx has developed the world’s first line of rationally-engineered live HSV-1 and HSV-2 vaccines that have been shown across 10 years of pre-clinical studies to be safe and highly immunogenic. RVx has also developed a novel type-specific diagnostic method, the ABVIC test, for serological testing of patients for HSV-1 and/or HSV-2 infection, which greatly improves upon the existing standard of care. Through the development of rationally-engineered live viral vaccines and a more accurate and reliable HSV diagnostic test, RVx is forging the path ahead to a brighter future.

Other Infographics
news image

Cancer Drugs Bring in Most Pharma Revenue

Infographic | February 25, 2020

Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow even larger by 2024. This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. According to Evaluate's calculations, oncology drugs reached US$123.8 billion in sales in 2018, more than double that of the next item on the list, drugs treating diabetes with US$48.5 billion dollars in sales. By 2024, cancer drug sales are expected to almost double to US$236.6 billion dollars.

Read More
news image

COVID-19 Summary as of March 13, 2020

Infographic | April 6, 2020

Biomedtracker and Trialtrove have a total of 307 clinical trials for the treatment of COVID-19. 152 initiated trials for the treatment of COVID-19. 155 Trials have been announced but have not yet begun recruitment.

Read More
news image

What Does The Pharma IndustryWant From CROs?

Infographic | June 16, 2022

Use Informa Pharma Intelligence’s marketing and pharma expertise to conduct industry research, produce engaging thought leadership content,

Read More
news image

Do patients actually watch all those pharma TV ads?

Infographic | January 13, 2020

Fewer than one in eight chronic-disease sufferers say they watch when a drug commercial comes on TV, according to one recent study of community users. And for the millennials among them, the percentage is even less so. That’s despite the $5.1 billion spent by biopharma on the medium in 2018. We take a look at these data points and many others from two recent studies on the media habits of patients and doctors.

Read More
news image

Smart Pharmacovigilance

Infographic | May 23, 2021

Pharmacovigilance (PV) is essential to all life science organizations, ensuring that patients' health comes first. Various trends in global healthcare have transformed today’s PV function into a corporate asset that enhances brand value and contributes to new growth opportunities. However, existing safety systems impose a significant cost burden to operate.

Read More
news image

Taking Pharmacy Benefits on a New Ride

Infographic | December 1, 2019

Rideshare companies like Uber and Lyft challenged the old way of doing things with a new approach. It’s not just about getting from point A to point B anymore, it’s about the experience, convenience and added value. The same applies to pass-through PBMs (pharmacy benefit managers) that are challenging the status quo to make prescriptions more affordable..

Read More

Spotlight

Rational Vaccines

Rational Vaccines (RVx) was formed in 2015 for the purpose of offering better solutions to stop the spread of herpes and alleviate the problems faced by people suffering with unrelenting, chronic disease. Based on the life work of Dr. Bill Halford, Associate Professor, Southern Illinois University Medical School, who studied herpes simplex virus 1 and 2 (HSV-1 and HSV-2) in a laboratory setting for 25 years, RVx has developed the world’s first line of rationally-engineered live HSV-1 and HSV-2 vaccines that have been shown across 10 years of pre-clinical studies to be safe and highly immunogenic. RVx has also developed a novel type-specific diagnostic method, the ABVIC test, for serological testing of patients for HSV-1 and/or HSV-2 infection, which greatly improves upon the existing standard of care. Through the development of rationally-engineered live viral vaccines and a more accurate and reliable HSV diagnostic test, RVx is forging the path ahead to a brighter future.

Events